Reuters logo
BRIEF-Pledpharma and Solasia enter license agreement on Pledox in Asia
November 20, 2017 / 6:38 AM / in 23 days

BRIEF-Pledpharma and Solasia enter license agreement on Pledox in Asia

Nov 20 (Reuters) - PLEDPHARMA AB (PUBL)

* PLEDPHARMA AND SOLASIA ENTER LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE PLEDOX® IN ASIA

* PLEDPHARMA AB (PUBL) - ‍SOLASIA WILL PAY UPFRONT, DEVELOPMENT, REGULATORY AND SALES MILESTONES OF UP TO ABOUT USD 83 MILLION​

* PLEDPHARMA AB (PUBL) - ‍SOLASIA WILL PAY INDUSTRY STANDARD ROYALTY RATES ON SALES​

* PLEDPHARMA AB (PUBL) - ‍WILL ALSO FULLY FINANCE AN EXPANSION OF PHASE III PROGRAM FOR PLEDOX​

* ‍TOTAL VALUE OF UPFRONT AND MILESTONE PAYMENTS IS UP TO JPY 9.3 BILLION​

* ‍PHASE III STUDIES ANTICIPATED TO BE INITIATED END OF 2017 WITH TOP LINE RESULTS EXPECTED IN 2020​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below